» Articles » PMID: 30890591

Chronic Kidney Disease, Cardiovascular Risk Markers and Total Mortality in Older Men: Cystatin C Versus Creatinine

Overview
Specialty Health Services
Date 2019 Mar 21
PMID 30890591
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: It remains uncertain whether cystatin C is a superior marker of renal function than creatinine in older adults. We have investigated the association between estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations based on creatinine (CKD-EPIcr) and cystatin C (CKD-EPIcys), and cardiovascular risk markers and mortality in older adults.

Methods: This is a cross-sectional and prospective study of 1639 British men aged 71-92 years followed up for an average of 5 years for mortality. Cox survival model and receiving operating characteristic analysis were used to assess the associations.

Results: The prevalence of chronic kidney disease (CKD) was similar using the two CKD-EPI equations, although cystatin C reclassified 43.9% of those with stage 3a CKD (eGFR 45-59 mL/min/1.73, moderate damage) to no CKD. However, CKD stages assessed using both CKD-EPIcr and CKD-EPIcys were significantly associated with vascular risk markers and with all-cause and cardiovascular disease mortality. In all men with CKD (eGFR <60 mL/min/1.73), the HRs (95% CI) for all-cause mortality after adjustment for cardiovascular risk factors compared with those with no CKD were 1.53 (1.20 to 1.96) and 1.74 (1.35 to 2.23) using CKD-EPIcr and CKD-EPIcys, respectively. Comparisons of the two CKD equations showed no significant difference in their predictive ability for mortality (difference in area under the curve p=0.46).

Conclusion: Despite reclassification of CKD stages, assessment of CKD using CKD-EPIcys did not improve prediction of mortality in older British men >70 years. Our data do not support the routine use of CKD-EPIcys for identifying CKD in the elderly British male population.

Citing Articles

Evaluation of Individual Cardiovascular Risk in Pre-Dialysis CKD Patients by Using the Ratio of Calcium-Phosphorus Product to Estimated Glomerular Filtration Rate (Ca × P/eGFR).

Kostov K, Simeonova T, Ignatov B, Eftimova T Biomedicines. 2025; 13(1).

PMID: 39857818 PMC: 11762089. DOI: 10.3390/biomedicines13010235.


Impact of cystatin C-derived glomerular filtration rate in patients undergoing transcatheter aortic valve implantation.

Kure Y, Okai T, Izumiya Y, Yoshida H, Mizutani K, Yamaguchi T Front Cardiovasc Med. 2023; 10:1035736.

PMID: 37187794 PMC: 10176087. DOI: 10.3389/fcvm.2023.1035736.


Clinical significance of serum CDC42 in the prediction of uremic vascular calcification incidence and progression.

Xu M, Pan M, An N, Chen R, Bai Y, He J Libyan J Med. 2023; 18(1):2194100.

PMID: 36987774 PMC: 10062235. DOI: 10.1080/19932820.2023.2194100.


Association of cystatin C levels with metabolic syndrome incidence: a nested case-control study with propensity score matching.

Yang T, Pei D J Int Med Res. 2021; 49(1):300060520986311.

PMID: 33446006 PMC: 7812406. DOI: 10.1177/0300060520986311.


Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project.

Rothenbacher D, Rehm M, Iacoviello L, Costanzo S, Tunstall-Pedoe H, Belch J BMC Med. 2020; 18(1):300.

PMID: 33161898 PMC: 7650190. DOI: 10.1186/s12916-020-01776-7.